Effect of Vitamin D3 Supplement in Glycemic Control of Pediatrics with Type 1 Diabetes Mellitus and Vitamin D Deficiency
Published: March 1, 2015 | DOI: https://doi.org/10.7860/JCDR/2015/.5683
Sakineh Mohammadian, Nasrin Fatahi, Hossein Zaeri, Mohammad Ali Vakili
1. Associate Professor, Neonatal and Children Health Reasearch Centre, Golestan University of Medical Science,
Neonatal and Children Health Research Center, Gorgan, Iran.
2. Pediatric Resident, Neonatal and Children Health Reasearch Centre, Golestan University of Medical Science,
Neonatal and Children Health Research Center, Gorgan, Iran.
3. Assistant Professor, Neonatal and Children Health Reasearch Centre, Golestan University of Medical Science,
Neonatal and Children Health Research Center, Gorgan, Iran.
4. Assistant Professor, Neonatal and Children Health Reasearch Centre, Golestan University of Medical Science,
Neonatal and Children Health Research Center, Gorgan, Iran.
Correspondence
Dr. Nasrin Fatahi,
Pediatric Resident, Golestan University of Medical Science, Neonatal and Children Health Research Center, Gorgan, Iran.
E-mail: nfty3063@yahoo.com
Background: Glycemic control prevents microvascular complications in patients with type I diabetes mellitus such as retinopathy, nephropathy and neuropathy that influences quality of life. Some studies show the immunomodulatory effect of vitamin D in synthesis and secretion of insulin.
Aims: In this study we evaluate glycemic changes after vitamin D3 supplement in children with type I diabetes mellitus and vitamin D deficiency.
Materials and Methods: In children with type I diabetes mellitus, level of vitamin D and HbA1C was measured. Patients with type I diabetes mellitus who had vitamin D deficiency (25OHD < 50 nmol/lit) treated with 300,000 units of vitamin D3. Calcium supplement (40mg/kg/day) divided in two doses in order to avoid hungry bone was also used. After three months, 25OHD and HbA1C were measured again. Differences, in mean ± SD HbA1C and 25OHD were evaluated before and after the study.
Results: Mean ± SD HbA1C was 9.73±1.85 before the study which was diminished to 8.55±1.91 after vitamin D3 supplement treatment. This decline has a significant difference (p-value < 0.0001). Mean ± SD 25OHD was 17.33±8.97 nmol/lit before the study which is increased to 39.31±14.38 nmol/lit after treatment with vitamin D3 supplement. This increase also has a significant difference (p-value < 0.0001). Vitamin D3 supplement causes the improvement of HbA1C in all groups of glycemic control including HbA1C <7.8, 7.8-9.9, and >9.9. This supplement transfer patients toward better glycemic control for the entire group (p-value < 0.0001).
Conclusion: Vitamin D3 supplement improves HbA1C in pediatrics with type I diabetes mellitus and vitamin D deficiency.
[
FULL TEXT ] | [ PDF]